5496-35-5
Chemical Structure
I-XW-053
- CAS No.: 5496-35-5
- Formula:C22H16N2O2
- Molecular Weight:340.38
IUPAC Name: 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoic acid
InChIKey: BCXPNUSETAZHEQ-UHFFFAOYSA-N
SMILES: O=C(O)C1=CC=C(C2=NC(C3=CC=CC=C3)=C(C4=CC=CC=C4)N2)C=C1
Biological Activity: I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
I-XW-053 | 99.71% | I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
I-XW-053 (Standard) | ≥98% | I-XW-053 (Standard) is the analytical standard of I-XW-053 (HY-103078). This product is intended for research and analytical applications. I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Kortagere S, et al. Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid. J Virol. 2012;86(16):8472-8481. [Content Brief]
- [2]. Chia T, et al. A Small Molecule, ACAi-028, with Anti-HIV-1 Activity Targets a Novel Hydrophobic Pocket on HIV-1 Capsid. Antimicrob Agents Chemother. 2021;65(10):e0103921. [Content Brief]
- [3]. Fricke T, et al. Human cytosolic extracts stabilize the HIV-1 core. J Virol. 2013;87(19):10587-10597. [Content Brief]
- [4]. Kortagere S, et al. Structure-activity relationships of a novel capsid targeted inhibitor of HIV-1 replication. J Chem Inf Model. 2014;54(11):3080-3090. [Content Brief]
Keywords
